Travere CEO Executes $1.8M Stock Sale and Simultaneous Option Exercise
Travere Therapeutics CEO Eric M. Dube sold 60,000 shares of company stock on April 1, 2026, in two tranches for roughly $1.8 million while exercising options to acquire 60,000 shares the same day. The transactions were conducted under a June 16, 2025 written 10b5-1 plan and follow a year in which the stock has risen 70%. Separately, the FDA pushed …